AstraZeneca Plc's shares dropped more than 10% after a trial of a new heart drug failed to help prevent heart problems in patients with a rare disease. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open Interest." (Source: Bloomberg)
AstraZeneca Plc's shares dropped more than 10% after a trial of a new heart drug failed to help prevent heart problems in patients with a rare disease. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open Interest." (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/97ce4ca5499929787e9cd23da7c4645f6ad7a829" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="AstraZeneca's Rare Drug Trial Failure Sends Shares Plunging"></iframe>
